216 related articles for article (PubMed ID: 7804956)
1. Antitopoisomerase and anticentromere antibodies in the sclerodermatosus complex.
Kallenberg CG
Clin Rev Allergy; 1994; 12(3):221-35. PubMed ID: 7804956
[No Abstract] [Full Text] [Related]
2. A case of systemic sclerosis with anticentromere, antitopoisomerase I, and anti-U1RNP antibodies.
Sato S; Ihn H; Soma Y; Shimozuma M; Shishiba T; Takehara K
J Rheumatol; 1993 Nov; 20(11):1961-3. PubMed ID: 8308786
[TBL] [Abstract][Full Text] [Related]
3. Immunoblotting on HEp-2 cells increases the detection of antitopoisomerase 1 antibodies in patients with systemic sclerosis.
Tamby MC; Servettaz A; Guilpain P; Tamas N; Berezné A; Batteux F; Reinbolt J; Guillevin L; Weill B; Mouthon L
Clin Immunol; 2007 Apr; 123(1):82-8. PubMed ID: 17258939
[TBL] [Abstract][Full Text] [Related]
4. [Coexistence of antitopoisomerase I and anticentromere antibodies in systemic sclerosis].
Garrido Rasco R; Castillo Palma MJ; García Hernández FJ; Sánchez Román J
Med Clin (Barc); 2010 Sep; 135(9):430-1. PubMed ID: 19767035
[No Abstract] [Full Text] [Related]
5. [Antinuclear, anticentromere and anti-ScL-70 antibodies in rheumatic diseases].
Ivanova SM; Melkumova KL; Il'in KV; Riazantseva TA; Piven' VA; Speranskiĭ AI
Lab Delo; 1990; (6):50-3. PubMed ID: 1699041
[TBL] [Abstract][Full Text] [Related]
6. Antikinetochore and antitopoisomerase I antibodies in systemic scleroderma: comparative study using immunoblotted recombinant antigens, immunofluorescence, and double immunodiffusion.
Jarzabek-Chorzelska M; Blaszczyk M; Kolacinska-Strasz Z; Chorzelski T; Jabłońska S; Maul GG
Arch Dermatol Res; 1990; 282(2):76-83. PubMed ID: 2162156
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of coexisting antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis: a EUSTAR group-based study.
Heijnen IA; Foocharoen C; Bannert B; Carreira PE; Caporali R; Smith V; Kumánovics G; Becker MO; Vanthuyne M; Simsek I; Bocelli-Tyndall C; Walker UA
Clin Exp Rheumatol; 2013; 31(2 Suppl 76):96-102. PubMed ID: 23101460
[TBL] [Abstract][Full Text] [Related]
8. Genetic and immunological differences between Japanese patients with diffuse scleroderma and limited scleroderma.
Satoh M; Akizuki M; Kuwana M; Mimori T; Yamagata H; Yoshida S; Homma M; Yamamoto T; Sasazuki T
J Rheumatol; 1994 Jan; 21(1):111-4. PubMed ID: 8151564
[TBL] [Abstract][Full Text] [Related]
9. Scleroderma: DR antigens, autoantibodies and clinical manifestations.
Alarcón GS; McCarty GA; Lanyon P; Phillips RM; Acton RT; Barger BO
Clin Exp Rheumatol; 1987; 5(4):317-21. PubMed ID: 3326691
[TBL] [Abstract][Full Text] [Related]
10. Bibliographical study of the concurrent existence of anticentromere and antitopoisomerase I antibodies.
Kikuchi M; Inagaki T
Clin Rheumatol; 2000; 19(6):435-41. PubMed ID: 11147751
[TBL] [Abstract][Full Text] [Related]
11. Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis.
Dick T; Mierau R; Bartz-Bazzanella P; Alavi M; Stoyanova-Scholz M; Kindler J; Genth E
Ann Rheum Dis; 2002 Feb; 61(2):121-7. PubMed ID: 11796397
[TBL] [Abstract][Full Text] [Related]
12. Autoantibodies in systemic sclerosis.
Vázquez-Abad D; Rothfield NF
Int Rev Immunol; 1995; 12(2-4):145-57. PubMed ID: 7650418
[TBL] [Abstract][Full Text] [Related]
13. [Clinical features of systemic sclerosis and association with antitopoisomerase-1 antibody and centromere pattern of antinuclear antibody].
Bertazzi GR; de Toledo RA; de Godoy MF; Geraldino GC; Polizelli DV; Fernandes GC; Pedroso CL; dos Santos FG; de Assis TM
Acta Reumatol Port; 2012; 37(1):9-17. PubMed ID: 22781510
[TBL] [Abstract][Full Text] [Related]
14. [Systemic sclerosis autoantibodies: what dermatologists must know].
Hüe S; Ingen-Housz-Oro S; Cosnes A
Ann Dermatol Venereol; 2013 Feb; 140(2):143-9. PubMed ID: 23395500
[No Abstract] [Full Text] [Related]
15. Anti-topoisomerase I autoantibodies in systemic sclerosis.
Czömpöly T; Simon D; Czirják L; Németh P
Autoimmun Rev; 2009 Jul; 8(8):692-6. PubMed ID: 19393194
[TBL] [Abstract][Full Text] [Related]
16. [Clinical, serological and immunogenetic studies of systemic sclerosis: a French response to the paper of JP Maddison].
Meyer O
Rev Rhum Mal Osteoartic; 1991 May; 58(5):371-3. PubMed ID: 1647545
[No Abstract] [Full Text] [Related]
17. Autoantibodies in systemic sclerosis (scleroderma): clues for clinical evaluation, prognosis and pathogenesis.
Grassegger A; Pohla-Gubo G; Frauscher M; Hintner H
Wien Med Wochenschr; 2008; 158(1-2):19-28. PubMed ID: 18286246
[TBL] [Abstract][Full Text] [Related]
18. HLA and ethnic associations among systemic sclerosis patients with anticentromere antibodies.
Morel PA; Chang HJ; Wilson JW; Conte C; Falkner D; Tweardy DJ; Medsger TA
Hum Immunol; 1995 Jan; 42(1):35-42. PubMed ID: 7751158
[TBL] [Abstract][Full Text] [Related]
19. Antinuclear autoantibody profile in systemic sclerosis patients who are negative for anticentromere and anti-topoisomerase I specificities.
Caramaschi P; Tonolli E; Biasi D; Caimmi C; Pieropan S; Dal Forno I; Scambi C; Adami S
Joint Bone Spine; 2015 May; 82(3):209-10. PubMed ID: 25543274
[No Abstract] [Full Text] [Related]
20. [Progress in clinical tests and the pathophysiological study of collagen diseases--anti-topoisomerase I antibodies and anticentromere antibodies].
Konndo H
Nihon Naika Gakkai Zasshi; 1998 Dec; 87(12):2409-13. PubMed ID: 9922659
[No Abstract] [Full Text] [Related]
[Next] [New Search]
